Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 7, 2000, Pages 486-492

  Sartorio, A ^a   Cattaneo, M ^a   Bucciarelli, P ^a   Bottasso, B ^a   Porretti, S ^a   Epaminonda, P ^a   Faglia, G ^a   Arosio, M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Acromegaly; Fibrinogen; Growth hormone deficiency; Plasminogen activator inhibitor 1 and coagulation variables

Indexed keywords

FIBRINOGEN; GROWTH HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SOMATOMEDIN C; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR;

ACROMEGALY; ADULT; ARTICLE; BLOOD CLOTTING; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GROWTH HORMONE DEFICIENCY; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOEMBOLISM;

ACROMEGALY; ADULT; AGE OF ONSET; ANTITHROMBIN III; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; MALE; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PITUITARY DISEASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN PRECURSORS; PROTHROMBIN; REFERENCE VALUES; SUPPORT, NON-U.S. GOV'T; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033780719     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-8145     Document Type: Article

References (32)

1. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
2. Adult growth hormone (GH)-deficient patients demonstrate heterogeniety between childhood onset and adult onset before and during human GH treatment
3. Cardiovascular disease and risk factors in adults with hypopituitarism
4. Haemostatic mechanisms are normal despite increased vascular mortality in hypopituitary adults
5. Increased cerebrovascular mortality in patients with hypopituitarism
6. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: A case-control study
7. Adipose tissue secretion and plasminogen activator inhibitor-1 in non obese and obese individuals
8. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
9. Serum treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults
10. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults
11. Growth hormone (GH) therapy in GH-deficient patients, the plasma factor VIII-von Willebrand factor complex and capillary fragility. A double-blind, placebo-controlled cross over study
12. PAI-1, obesity, insulin resistance and risk of cardiovascular events
13. Fibrinogen, cigarette smoking and risk of cardiovascular disease: Onsights from the Framingham study
14. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
15. Elevated fibrinogen levels decrease following treatment of acromegaly
16. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults
17. Relationships of plasminogen activator inhibitor activity and lipoprotein (a) with insulin, testosterone, 17-beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls
18. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park heart study
19. Activation of the coagulant pathway in cigarette smokers
20. Body composition and energy expenditure in acromegaly
21. Determinants of clinical outcome and survival in acromegaly
22. Premature mortality due to cardiovascular disease in hypopituitarism
23. Cardiovascular risk factors in adult patients with growth hormone deficiency
24. Growth hormone and the heart
25. High plasma levels of plasminogen activator inhibitor in adults with childhood-onset growth hormone deficiency. Letter to the editor
26. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states
27. Haemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh artery study
28. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
29. Gerinnerungsphysiologische schnellmethode zur bestimmung des fibrinogens
30. Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: Relation to growth hormone levels and insulin-like growth factor I
31. Fibrinogen as a risk for stroke and myocardial infarction
32. Mortality in acromegaly